A new CEO, same company — but different vibes
Juvisé Pharmaceuticals just gave its leadership team a makeover. At its April 15 board meeting, the company officially approved Frédéric Mascha’s move out of the CEO chair and into the role of executive chairman and chairman of the supervisory committee.
Enter Renaud Sermondade
The bigger move for investors: Renaud Sermondade has been tapped as the group’s new CEO, starting July 1, 2026. In other words, the company is swapping the person steering the ship, not changing the ship itself.
Why you should care
CEO changes can matter because they often come with a new playbook — think cost cuts, new growth priorities, portfolio tweaks, or a different appetite for M&A. Sometimes it’s a drama-filled overhaul; sometimes it’s just the board saying, “New boss, same spreadsheet.”
For now, the news reads more like a planned handoff than a crisis exit. But when leadership changes land, investors usually want to know one thing: is this about continuity, or a quiet pivot?
Big picture: this is a classic “watch the next few quarters” story. The market will be looking for clues on whether Sermondade brings a fresh strategy — or just a fresh title.